Targeting PPAR ligands as possible approaches for metabolic reprogramming of T cells in cancer immunotherapy

Bahrambeigi, S and Seifi, L and Shafiei Irannejad, V and Sohrabi, F and Molaparast, M and Fani, S and Faraji, A.R (2020) Targeting PPAR ligands as possible approaches for metabolic reprogramming of T cells in cancer immunotherapy. Immunology Letters, 220. pp. 32-37.

Preview

Text 1789.pdf Download (912kB) | Preview

Abstract

Despite the prominent progress in understanding cancer immunosurveillance mechanisms, there are some types of problems which have been identified to hinder effective and successful immunotherapy of cancers. Such problems have been ascribed to the tumor abilities in the creation of a tolerant milieu that can impair immune responses against cancer cells. In the present study, we represent possible approaches for metabolic repro- gramming of T cells in cancer immunotherapy to overcome tumor metabolic impositions on immune responses against cancer cells. Metabolic suppression of effector immune cells in tumor milieu is one of the important strategies recruited by tumor cells to escape from immunogenic cell death. We have investigated the metabolic reprogramming of T cells as a method and a possible new target for cancer immunotherapy. Synergic effects of PPAR ligands in immunotherapy of cancers on the metabolic reprogramming of T cells have been noticed by several studies as a new target of cancer immunotherapy. The current wealth of data like this promises a future scenario which the consideration of metabolic restriction in the tumor microenvironment and administration of therapeutic agents such as PPAR ligands to overcome metabolic restrictions on T cells (refreshing their func- tionality) may be effective and enhance the accountability and efficacy of cancer immunotherapy.

Actions (login required)

View Item